NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Gyre Therapeutics, Inc. (GYRE) Stock Analysis

Gyre Therapeutics, Inc. (GYRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GYRE

$6.86

+$0.42 (+6.52%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GYRE with… →

GYRE Key Statistics

As of Sep 4, 2026
Trading
Open
$6.44
Previous Close
$6.44
Day's Range
6.41–6.89
52-Week Range
5.44–9.42
Volume
56.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
4.83
Valuation
Market Cap
$727.39M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
114.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.21
Financials (FY)
Revenue (FY)
$116.59M+10.24%
Net Income (FY)
$5.03M−58.40%
Profit marginThe share of revenue left as profit after all costs and taxes.
−19.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
106.03M
1-Year Return
−9.50%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
76.30K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GYRE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.83%
2025−41.65%
2024−52.90%
2023+422.01%
2022+121.54%
2021−85.58%
2020−7.34%
2019−13.69%
2018−42.16%
2017+39.90%
2016 (partial year)−56.08%

As of September 4, 2026.

GYRE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$116.59M$5.03M4.3%
2024$105.76M$12.09M11.4%
2023$113.45M−$92.93M−81.9%
2022$102.29M$2.30M2.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$116.59M$111.17M$11.49M$5.03M4.3%
2024$105.76M$101.87M$16.23M$12.09M11.4%
2023$113.45M$108.81M$19.21M−$92.93M−81.9%
2022$102.29M$97.50M$9.20M$2.30M2.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GYRE Valuation vs Biotechnology Median

Median of 656 stocks
MetricGYREBiotechnology medianvs median
P/S ratio6.6215.2657% below
Profit margin−19.33%0.00%19.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Gyre Therapeutics, Inc. (GYRE) is capitalised at $727.39M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 625.

The most recent close on file for GYRE is $6.86, dated September 4, 2026. That is +$0.42 (+6.52%) against the previous close. Over the past 52 weeks the price has ranged from $5.44 to $9.42. The latest close sits 26.1% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $116.59M. That is +10.24% against the prior fiscal year, when revenue was $105.76M. Net income for the same year was $5.03M. That is −58.40% against the prior fiscal year. The reported profit margin is −19.33%. That is 19.3 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.21.

Across the 4 fiscal years on file, revenue moves from $102.29M in 2022 to $116.59M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 114.33. Measured against sales, the shares trade at 6.62 times revenue. On price-to-sales that is 56.61% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 4.83. Daily returns over the trailing 10 years annualize to a volatility of 136.14%. The trailing one-year price return is −9.50%. Measured over 10 years, that is −17.29% a year compounded.

Growth & Income

The record shows no dividend for GYRE.

So far in 2026 the price is −2.83%. The strongest complete calendar year on file is 2023 at +422.01%; the weakest is 2021 at −85.58%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Gyre Therapeutics, Inc. (GYRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Gyre Therapeutics, Inc. GYRE $727.39M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Gyre Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Visit website →